ELI LILY

AACI

This critical trial explores Donanemab‘s potential in preventing the progression of early Alzheimer’s disease by targeting amyloid plaques in the brain. This N3pG antibody aims to halt or slow cognitive decline. This study holds promise for early intervention in Alzheimer’s disease’s progression.

Status: ACTIVE, NOT RECRUITING

FDA Approved

Study Details

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.